Sano blog | Charlotte Guzzo

Patient engagement through the precision medicine lifecycle

precision medicine patient engagement

The long game: Precision trials shouldn’t start from zero every time

Precision medicine sponsors invest heavily to identify, educate, screen, consent, genotype, and support rare patients. In many programs, once a trial ends, that...

patient recruitment patient engagement

The psychology of kit return: What drives completion?

Genetic testing has become a core component of patient identification and stratification in modern clinical trials, particularly in rare disease and precision m...

Patient engagement in rare disease trials

rare disease patient engagement

Patient engagement and education insights from rare disease trials

Recruiting and retaining patients in rare disease and genomic medicine research requires more than outreach. Many participants need support understanding geneti...

rare disease patient engagement

Barriers to long-term follow-up in cell and gene therapy

Cell and gene therapy (CGT) programs are committing to 10-15 years of follow-up – often without the infrastructure to support it. FDA guidance for certain gene ...

rare disease protocol design

Rethinking drug approval for ultra-rare disease: Inside the UK’s n-of-1 ASO trial

Last week, the rare disease field celebrated another breakthrough. A teenage girl with an ultra-rare genetic neurodegenerative disease was treated with a bespok...

Effective site enablement in precision medicine

patient recruitment patient engagement

What strong site enablement really looks like: Lessons from Sano’s site expert

Trial sponsors often assume that site enablement is largely complete once a trial launches. Feasibility assessments, training materials, and startup timelines a...

thought leadership rare disease patient engagement

Redefining accessibility in cell and gene therapies

Cell and gene therapy continues to advance across a growing number of rare genetic conditions. As more of these therapies move closer to the clinic, a central t...

precision medicine protocol design

Lessons from recent FDA actions in precision medicine

Over the past few years, several cell and gene therapies (CGTs) in precision medicine have received FDA Complete Response Letters (CRLs). As the agency increase...

Regulatory signals for precision medicine trial sponsors

rare disease protocol design

Top five regulatory signals sponsors can act on now

The FDA’s activity in 2025 reflected a mix of scientific progress and operational instability. Precision medicine programs benefitted from new draft guidance, r...

Behind the scenes with a patient navigator lead

patient recruitment patient engagement

Behind the scenes at Sano: Navigating the patient journey

Advocating for patients is one of the core pillars of Sano’s mission. Our approach to clinical trials is patient-centered and entails deep and meaningful engage...

Clinical research blog

The long game: Precision trials shouldn’t start from zero every time

The psychology of kit return: What drives completion?

Patient engagement and education insights from rare disease trials

Barriers to long-term follow-up in cell and gene therapy

Rethinking drug approval for ultra-rare disease: Inside the UK’s n-of-1 ASO trial

What strong site enablement really looks like: Lessons from Sano’s site expert

Redefining accessibility in cell and gene therapies

Lessons from recent FDA actions in precision medicine

Top five regulatory signals sponsors can act on now

Behind the scenes at Sano: Navigating the patient journey

Join the email list